BeOne Medicines Ltd
54 hedge funds and large institutions have $504M invested in BeOne Medicines Ltd in 2016 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 19 increasing their positions, 3 reducing their positions, and 10 closing their positions.
533% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 3
150% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 10
61% more capital invested
Capital invested by funds: $313M → $504M (+$191M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
38% more funds holding
Funds holding: 39 → 54 (+15)
3.3% more ownership
Funds ownership: 0% → 3.3% (+3.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$55.3M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$34.1M |
| 3 |
O
OrbiMed
New York
|
+$28.4M |
| 4 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
+$20.9M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$5.04M |
| 2 |
PA
Perceptive Advisors
New York
|
-$4.07M |
| 3 |
VMI
VHCP Management II
New York
|
-$3.67M |
| 4 |
CC
CQS Cayman
Camana Bay, Grand Cayman,
Cayman Islands
|
-$2.26M |
| 5 |
VM
VHCP Management
New York
|
-$1.57M |
ONC Hedge Fund Activity: Q4 2016 in Review
54 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines Ltd (ONC) for Q4 2016, worth a combined $504M — up 61% from $313M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ONC positions and 10 closed out — a net gain of 15 holders — while 19 added to existing stakes and 3 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $55.3M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $5.04M sold.
- 54 institutional investors held BeOne Medicines Ltd (ONC) as of Q4 2016, up from 39 in Q3 2016.
- Funds reported $504M of BeOne Medicines Ltd stock for Q4 2016, up 61% quarter-over-quarter.
- 25 funds opened new BeOne Medicines Ltd positions in Q4 2016 and 10 closed out, a net change of +15 holders.
- The largest BeOne Medicines Ltd buyer in Q4 2016 was Baker Bros. Advisors, an estimated $55.3M added.
- The largest BeOne Medicines Ltd seller in Q4 2016 was EcoR1 Capital, an estimated $5.04M sold.
Based on aggregated 13F filings for Q4 2016.